ArticleWorld journal of surgical oncology2015
Hepatoid carcinoma of the pancreas.
Article in World journal of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Imaging of pancreatic hepatoid adenocarcinoma: a scoping review.Quantitative imaging in medicine and surgery · 2026Review
- Marked response to dabrafenib plus trametinib in a patient with BRAF V600E-mutant pancreatic hepatoid carcinoma: a case report and systematic analysis of 57 cases.Frontiers in oncology · 2026Article
- Rare pancreatic ductal adenocarcinoma variants and other malignant epithelial tumors: a comprehensive clinical and radiologic review.Japanese journal of radiology · 2025Review
- Pancreatic hepatoid adenocarcinoma with neuroendocrine differentiation and elevated AFP: a case report.Frontiers in oncology · 2025Article
- Pancreatic hepatoid carcinoma: a case report.AME case reports · 2025Article
- Histological variants of pancreatic ductal adenocarcinoma: a survival analysis.Langenbeck's archives of surgery · 2024Article
- Primary hepatoid adenocarcinoma of the lung with extremely elevated serum AFP: a case report and literature review.Frontiers in oncology · 2024Article
- Focal Hepatocellular Carcinoma in Pancreas.Journal of medical cases · 2024Article
- Case report and literature analysis: pancreatic hepatoid carcinoma with multiple lymph node metastases progressing to liver metastasis after pancreaticoduodenectomy.Frontiers in oncology · 2024Article
- A narrative review on rare types of pancreatic cancer: should they be treated as pancreatic ductal adenocarcinomas?Therapeutic advances in medical oncology · 2024Review
- A pancreatic adenocarcinoma mimicking hepatoid carcinoma of uncertain histogenesis: A case report and literature review.Oncology letters · 2023Article
- Mediastinal Hepatoid Adenocarcinoma Treated With Arterial Interventional Therapy: A Case Report and Review of Literature.Frontiers in oncology · 2022Article
- Hepatoid adenocarcinoma of the lung: An analysis of the Surveillance, Epidemiology, and End Results (SEER) database.Open medicine (Warsaw, Poland) · 2021Review
- Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology.International journal of molecular sciences · 2020Review
- Hepatoid carcinoma of the pancreas: A case report and review of the literature.World journal of clinical cases · 2020Article
- Pure pancreatic hepatoid carcinoma: a surgical case report and literature review.Surgical case reports · 2019Article
- AFP-producing hepatoid adenocarcinoma (HAC) of peritoneum and omentum: a case report and literature review.OncoTargets and therapy · 2019Article
- Primary hepatoid adenocarcinoma of the orbit.American journal of ophthalmology case reports · 2017Article
- Hepatoid Carcinoma of the Pancreas: A Case Report and Review of the Literature.Case reports in pancreatic cancer · 2015Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatoid carcinoma of the pancreas is extremely rare. This article tries to summarize the clinical features and outcomes of pancreatic hepatoid carcinoma.
methodsThe data pool for analysis includes the case we encountered with hepatoid carcinoma of the pancreas and the reported cases in the literature.
resultsTwenty-three cases of hepatoid carcinoma of the pancreas were analyzed. This tumor occurred more frequently in male than in female patients (69.6 vs. 30.4 %). Tumor sizes range from 0.5 to 11.0 cm with median of 6.0 cm. The most common symptom was epigastric pain (36.4 %). When the tumor locates at pancreatic head, nausea/vomiting (62.5 %) is more common, followed by jaundice and epigastric pain (50.0 %). For those at pancreatic body-tail, 42.9 % of the patients presented no symptom. Alpha-fetoprotein (AFP) was abnormally elevated in 60 % of the cases. Hepatoid carcinoma in the pancreas could be either pure form or mixed form with other malignancy (40.9 %), with the most common coexisted pathology of malignant neuroendocrine tumor (22.7 %). Metastasis occurred in 36.4 % of the cases at the diagnosis of this tumor, including liver metastasis in 31.8 % and lymph node metastasis in 21.1 %. The overall 1-year survival rate was 71.1 % and 5-year 40.4 %, with a median of 13.0 months. Unresectability, hepatic, and lymph node metastases are associated with negative impact on survival outcome.
conclusionsElevation of serum AFP may be a clue leading to the diagnosis of pancreatic hepatoid carcinoma. This tumor could be mixed form with other malignancy. Surgical resection should be the treatment of choice whenever possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.